Targeted therapy in renal cell carcinoma

G. Gasparini, R. Longo

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Renal cell carcinoma (RCC) is diagnosed in approximately 170,000 patients worldwide annually, resulting in 82,000 deaths. The 5-year survival rate for metastatic RCC (mRCC) is <10% and up to 30% of patients treated with radical nephrectomy are at risk of relapse. Cytokine therapy, such as interferon-α (INF-α) and interleukin-2 (IL-2), has been the standard of therapy for mRCC for many years. Recently, the better understanding of the molecular pathogenesis of RCC has led to the development of a number of new targeted drugs, particularly anti-VEGF (vascular endothelial growth factor) drugs and mammalian target of rapamycin (mTOR) inhibitors that have been approved for the treatment of advanced disease, and many other compounds are undergoing preclinical or early clinical evaluation. However, several questions remain to be addressed, including: The identification of the optimal methodological approach in the clinical development of these new agents and of the best clinical setting to evaluate them, the identification of the optimal schedule of treatment and of surrogate predictive markers of activity that could lead to a better selection of patients, the evaluation of these agents in other histological subtypes, particularly papillary and chromophobe RCC, and finally, the management of new emerging toxicity.

Original languageEnglish
Title of host publicationAngiogenesis & Therapeutic Targets In Cancer
PublisherBentham Science Publishers Ltd.
Pages180-189
Number of pages10
ISBN (Print)9781608055739
DOIs
Publication statusPublished - 2010

Fingerprint

Renal Cell Carcinoma
Vascular Endothelial Growth Factor A
Therapeutics
Proxy
Sirolimus
Nephrectomy
Pharmaceutical Preparations
Interferons
Interleukin-2
Appointments and Schedules
Survival Rate
Biomarkers
Cytokines
Recurrence

Keywords

  • Angiogenesis
  • Bevacizumab
  • Everolimus
  • Renal cell carcinoma
  • Sorafenib
  • Sunitinib
  • Temsirolimus

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Gasparini, G., & Longo, R. (2010). Targeted therapy in renal cell carcinoma. In Angiogenesis & Therapeutic Targets In Cancer (pp. 180-189). Bentham Science Publishers Ltd.. https://doi.org/10.2174/978160805007911001010180

Targeted therapy in renal cell carcinoma. / Gasparini, G.; Longo, R.

Angiogenesis & Therapeutic Targets In Cancer. Bentham Science Publishers Ltd., 2010. p. 180-189.

Research output: Chapter in Book/Report/Conference proceedingChapter

Gasparini, G & Longo, R 2010, Targeted therapy in renal cell carcinoma. in Angiogenesis & Therapeutic Targets In Cancer. Bentham Science Publishers Ltd., pp. 180-189. https://doi.org/10.2174/978160805007911001010180
Gasparini G, Longo R. Targeted therapy in renal cell carcinoma. In Angiogenesis & Therapeutic Targets In Cancer. Bentham Science Publishers Ltd. 2010. p. 180-189 https://doi.org/10.2174/978160805007911001010180
Gasparini, G. ; Longo, R. / Targeted therapy in renal cell carcinoma. Angiogenesis & Therapeutic Targets In Cancer. Bentham Science Publishers Ltd., 2010. pp. 180-189
@inbook{be96abd44375440ea5fba2e949522d57,
title = "Targeted therapy in renal cell carcinoma",
abstract = "Renal cell carcinoma (RCC) is diagnosed in approximately 170,000 patients worldwide annually, resulting in 82,000 deaths. The 5-year survival rate for metastatic RCC (mRCC) is <10{\%} and up to 30{\%} of patients treated with radical nephrectomy are at risk of relapse. Cytokine therapy, such as interferon-α (INF-α) and interleukin-2 (IL-2), has been the standard of therapy for mRCC for many years. Recently, the better understanding of the molecular pathogenesis of RCC has led to the development of a number of new targeted drugs, particularly anti-VEGF (vascular endothelial growth factor) drugs and mammalian target of rapamycin (mTOR) inhibitors that have been approved for the treatment of advanced disease, and many other compounds are undergoing preclinical or early clinical evaluation. However, several questions remain to be addressed, including: The identification of the optimal methodological approach in the clinical development of these new agents and of the best clinical setting to evaluate them, the identification of the optimal schedule of treatment and of surrogate predictive markers of activity that could lead to a better selection of patients, the evaluation of these agents in other histological subtypes, particularly papillary and chromophobe RCC, and finally, the management of new emerging toxicity.",
keywords = "Angiogenesis, Bevacizumab, Everolimus, Renal cell carcinoma, Sorafenib, Sunitinib, Temsirolimus",
author = "G. Gasparini and R. Longo",
year = "2010",
doi = "10.2174/978160805007911001010180",
language = "English",
isbn = "9781608055739",
pages = "180--189",
booktitle = "Angiogenesis & Therapeutic Targets In Cancer",
publisher = "Bentham Science Publishers Ltd.",

}

TY - CHAP

T1 - Targeted therapy in renal cell carcinoma

AU - Gasparini, G.

AU - Longo, R.

PY - 2010

Y1 - 2010

N2 - Renal cell carcinoma (RCC) is diagnosed in approximately 170,000 patients worldwide annually, resulting in 82,000 deaths. The 5-year survival rate for metastatic RCC (mRCC) is <10% and up to 30% of patients treated with radical nephrectomy are at risk of relapse. Cytokine therapy, such as interferon-α (INF-α) and interleukin-2 (IL-2), has been the standard of therapy for mRCC for many years. Recently, the better understanding of the molecular pathogenesis of RCC has led to the development of a number of new targeted drugs, particularly anti-VEGF (vascular endothelial growth factor) drugs and mammalian target of rapamycin (mTOR) inhibitors that have been approved for the treatment of advanced disease, and many other compounds are undergoing preclinical or early clinical evaluation. However, several questions remain to be addressed, including: The identification of the optimal methodological approach in the clinical development of these new agents and of the best clinical setting to evaluate them, the identification of the optimal schedule of treatment and of surrogate predictive markers of activity that could lead to a better selection of patients, the evaluation of these agents in other histological subtypes, particularly papillary and chromophobe RCC, and finally, the management of new emerging toxicity.

AB - Renal cell carcinoma (RCC) is diagnosed in approximately 170,000 patients worldwide annually, resulting in 82,000 deaths. The 5-year survival rate for metastatic RCC (mRCC) is <10% and up to 30% of patients treated with radical nephrectomy are at risk of relapse. Cytokine therapy, such as interferon-α (INF-α) and interleukin-2 (IL-2), has been the standard of therapy for mRCC for many years. Recently, the better understanding of the molecular pathogenesis of RCC has led to the development of a number of new targeted drugs, particularly anti-VEGF (vascular endothelial growth factor) drugs and mammalian target of rapamycin (mTOR) inhibitors that have been approved for the treatment of advanced disease, and many other compounds are undergoing preclinical or early clinical evaluation. However, several questions remain to be addressed, including: The identification of the optimal methodological approach in the clinical development of these new agents and of the best clinical setting to evaluate them, the identification of the optimal schedule of treatment and of surrogate predictive markers of activity that could lead to a better selection of patients, the evaluation of these agents in other histological subtypes, particularly papillary and chromophobe RCC, and finally, the management of new emerging toxicity.

KW - Angiogenesis

KW - Bevacizumab

KW - Everolimus

KW - Renal cell carcinoma

KW - Sorafenib

KW - Sunitinib

KW - Temsirolimus

UR - http://www.scopus.com/inward/record.url?scp=84884457837&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84884457837&partnerID=8YFLogxK

U2 - 10.2174/978160805007911001010180

DO - 10.2174/978160805007911001010180

M3 - Chapter

SN - 9781608055739

SP - 180

EP - 189

BT - Angiogenesis & Therapeutic Targets In Cancer

PB - Bentham Science Publishers Ltd.

ER -